Brokerage Firm Rating on Esperion Therapeutics (ESPR)

Esperion Therapeutics (ESPR) : Zacks Investment Research ranks Esperion Therapeutics (ESPR) as 2, which is a Buy recommendation. 2 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. A total of 7 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 10 research analysts is 2.5, which indicates as a Buy.

Esperion Therapeutics (ESPR) : The highest short term price target forecast on Esperion Therapeutics (ESPR) is $64 and the lowest target price is $11. A total of 10 equity analysts are currently covering the company. The average price of all the analysts is $23.3 with a standard deviation of $16.26.


Company shares have received an average consensus rating of Hold for the current week Esperion Therapeutics (NASDAQ:ESPR): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $10.73 and $10.44 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $10.89. The buying momentum continued till the end and the stock did not give up its gains. It closed at $10.87, notching a gain of 1.97% for the day. The total traded volume was 288,475 . The stock had closed at $10.66 on the previous day.

In a related news, Mcgovern Mark E, director of Esperion Therapeutics, Inc., executed a transaction worth $50,000 on July 5, 2016. A total of 5,000 shares were purchased at an average price of $10. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.

Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of patients with hypercholesterolemia and other cardio-metabolic risk markers. The Companys primary activities include conducting research and development activities, including nonclinical, preclinical and clinical testing, performing business and financial planning, recruiting personnel, and raising capital. ETC-1002, the Companys lead product candidate, is an orally available, once-daily small molecule designed to lower LDL-cholesterol levels and avoid the side effects associated with other LDL-cholesterol lowering therapies currently available. ETC-1002 is being developed for patients with hypercholesterolemia. One completed Phase IIb clinical study and a second that is nearing completion build upon a Phase I and Phase II clinical development program for ETC-1002.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *